Search details
1.
Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk.
Ann Surg Oncol
; 31(5): 3339-3349, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38372861
2.
Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Cancer
; 129(9): 1411-1418, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36811344
3.
Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation.
Cancer
; 129(14): 2152-2160, 2023 07 15.
Article
in English
| MEDLINE | ID: mdl-37042570
4.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
; 23(4): 540-552, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35358455
5.
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
Int J Cancer
; 150(2): 279-289, 2022 01 15.
Article
in English
| MEDLINE | ID: mdl-34528705
6.
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).
Angiogenesis
; 25(1): 47-55, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34028627
7.
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
Br J Cancer
; 126(2): 265-274, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34616010
8.
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
N Engl J Med
; 381(4): 317-327, 2019 07 25.
Article
in English
| MEDLINE | ID: mdl-31157963
9.
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Proc Natl Acad Sci U S A
; 116(18): 9008-9013, 2019 04 30.
Article
in English
| MEDLINE | ID: mdl-30975761
10.
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
Br J Cancer
; 124(3): 564-566, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33100328
11.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol
; 21(10): 1353-1365, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32919526
12.
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
Invest New Drugs
; 38(2): 457-467, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31065954
13.
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Cancer
; 125(10): 1629-1636, 2019 05 15.
Article
in English
| MEDLINE | ID: mdl-30645764
14.
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Pharmacogenet Genomics
; 29(6): 123-131, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30889042
15.
ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
Ann Surg Oncol
; 31(6): 3785-3786, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38502295
16.
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
Ann Surg Oncol
; 26(13): 4489-4497, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-31418130
17.
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
Eur Radiol
; 29(2): 682-688, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-29967955
18.
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Cancer
; 124(7): 1374-1382, 2018 04 01.
Article
in English
| MEDLINE | ID: mdl-29338080
19.
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.
World J Surg
; 42(4): 1036-1045, 2018 04.
Article
in English
| MEDLINE | ID: mdl-28948332
20.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol
; 18(9): 1261-1273, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28729154